Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528072 · ClinicalTrials.gov registry record · NA
Dynesys Spinal System Post Market 522 Study
A NA study, sponsored by Zimmer Biomet.
- Terminated
- Registry status
- NA
- Development phase
- 153
- Enrollment target
NCT01528072: Clinical Trial NA study, sponsored by Zimmer Biomet.
NCT01528072 is a NA study that was terminated before completion, run by Zimmer Biomet. The registered enrollment target is 153 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01528072, a NA study, was terminated before completion, sponsored by Zimmer Biomet.
- TERMINATED
- Registry status
- NA
- Development phase
- 153 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and fusion rates following posterior lateral fusion with the Dynesys Spinal System used as an adjunct to fusion and compare to literature control.
Primary Outcome
Fusion was defined by meeting three criteria: * rotation \< 5° between motion segments on flexion-extension radiographs * translation \< 3 mm between motion segments on flexion-extension radiographs * presence of bridging bone. Fusion assessment for each patient was categorized as one of the four defined outcomes: fused, not fused, partial fusion, or UA (unable to assess). Efficacy was confirmed by the achievement of fusion in the experimental group when compared to the rate established in a li
Interventions
- DEVICE Dynesys Spinal System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2012-03 |
| Est. Completion | 2017-04 |
| Phase | NA |
Why NCT01528072 stopped before completion
NCT01528072 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 1 intervention - of which Dynesys Spinal System is the first listed.
NCT01528072 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01528072 about?
NCT01528072 is a clinical study titled "Dynesys Spinal System Post Market 522 Study". The purpose of this study is to assess the safety and fusion rates following posterior lateral fusion with the Dynesys Spinal System used as an adjunct to fusion and compare to literature control.
What is the current status of trial NCT01528072?
This trial is currently terminated. It is a NA study. The enrollment target is 153 participants. The study started on 2012-03. Estimated completion is 2017-04.
What interventions are being tested in trial NCT01528072?
The interventions under investigation include: Dynesys Spinal System (DEVICE).
Who is sponsoring clinical trial NCT01528072?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01528072's enrollment target sits among peer trials
153 656th of 2000 higher than 1,343 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia